TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23735728

Group type: EXPERIMENTAL
Intervention: Preoperative monocyte counts
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Preoperative C-reactive protein (CRP) levels
Number of subjects: 115
Study: 23736357

Group type: EXPERIMENTAL
Intervention: Parental policies supporting physical activity (PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limiting access to unhealthy foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role modeling of healthy eating behaviors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limiting access to unhealthy foods and role modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental policies supporting family meals
Number of subjects: 0
Study: 23737404

Group type: EXPERIMENTAL
Intervention: Lacosamide (100 mg single oral dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lacosamide in patients with ESRD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lacosamide in patients with mild-to-moderate renal impairment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lacosamide in patients with severe renal impairment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lacosamide in patients on hemodialysis
Number of subjects: 40
Study: 23738544

Group type: EXPERIMENTAL
Intervention: Eculizumab for 26 weeks (trial 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Eculizumab for 26 weeks (trial 2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Eculizumab (both trials)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Eculizumab (trial 1)
Number of subjects: 37
Study: 23738760

Group type: EXPERIMENTAL
Intervention: Pre-transplant infusion of autologous MSC
Number of subjects: 2

Group type: COMPARATOR
Intervention: Induction therapy without basiliximab
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not given MSC)
Number of subjects: 2
Study: 23739141

Group type: EXPERIMENTAL
Intervention: EVR group (n = 76)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-EVR control group (n = 68)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ritonavir use
Number of subjects: 144
Study: 23739218

Group type: EXPERIMENTAL
Intervention: Fasting glucose assessment
Number of subjects: 226

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Fasting glucose >7.0 mmol/l
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Fasting glucose between 6.1 and 7.0 mmol/l
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Fasting glucose <6.1 mmol/l
Number of subjects: 226
Study: 23739725

Group type: EXPERIMENTAL
Intervention: Pathways to Health obesity prevention program
Number of subjects: 0
Study: 23740195

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) trial
Number of subjects: 0
Study: 23740728

Group type: EXPERIMENTAL
Intervention: Enzyme immunoassay kit detecting serum IgA antibody to glycopeptidolipid core antigen from MAC
Number of subjects: 0
Study: 23740965

Group type: EXPERIMENTAL
Intervention: Wavelet augmented ultrasound
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Multivariate classifier
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Statistical modelling of wavelet coefficients
Number of subjects: 52
Study: 23741398

Group type: EXPERIMENTAL
Intervention: Genomic insertions containing HLA-DRB5, DRB1 and DQA1/DRA genes in the MHC region (chromosome 6p21.3)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Segmental insertion on chromosome 1 containing NBPF4, NBPF5, STXMP3, CLCC1, and GPSM2 genes
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Segmental deletions spanning PRR20, PCDH17 and PCH68 genes on chromosome 13
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Genomic insertion on chromosome 17 containing NSF, ARL17 and LRRC37A genes
Number of subjects: 994
Study: 23742705

Group type: EXPERIMENTAL
Intervention: Five-word test
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Cognitive disorders examination test
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Verbal fluency test
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Memory consultation at University Hospital
Number of subjects: 620
Study: 23743475

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-α (IFNα)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New generation of HCV-specific antiviral drugs
Number of subjects: 0
Study: 23744173

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 27

Group type: COMPARATOR
Intervention: Adalimumab vs Etanercept
Number of subjects: 27

Group type: COMPARATOR
Intervention: Infliximab vs Etanercept
Number of subjects: 27
Study: 23744583

Group type: EXPERIMENTAL
Intervention: Cranial radiation therapy (CRT)
Number of subjects: 102
Study: 23745006

Group type: EXPERIMENTAL
Intervention: Phenotype A (low MA turnover and normal RT)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Phenotype B (low MA turnover and increased central RT)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Phenotype C (high MA turnover)
Number of subjects: 410
Study: 23745581

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF therapy
Number of subjects: 223
Study: 23746612

Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes with visible RNFL defects
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy eyes
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sectors with visible RNFL defects in glaucomatous eyes
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sectors without visible RNFL defects in glaucomatous eyes
Number of subjects: 66
Study: 23746966

Group type: EXPERIMENTAL
Intervention: MSC1992371A (oral aurora kinase inhibitor) at maximum tolerated doses of 37 mg/m(2)/day (days 1-3 and 8-10)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MSC1992371A (oral aurora kinase inhibitor) at maximum tolerated doses of 28 mg/m(2)/day (days 1-6)
Number of subjects: 75
Study: 23746988

Group type: EXPERIMENTAL
Intervention: CT colonography surveillance
Number of subjects: 243
Study: 23747159

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study: 23748484

Group type: COMPARATOR
Intervention: Men
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1140
Study: 23748977

Group type: EXPERIMENTAL
Intervention: Headache occurrence in males
Number of subjects: 4431

Group type: EXPERIMENTAL
Intervention: Headache occurrence in females
Number of subjects: 4431

Group type: EXPERIMENTAL
Intervention: Headache associated with IS or TIA in posterior cerebral territory
Number of subjects: 4431

Group type: EXPERIMENTAL
Intervention: Headache associated with IS or TIA in vertebrobasilar arteries
Number of subjects: 4431

Group type: EXPERIMENTAL
Intervention: Headache occurrence related to lesion size
Number of subjects: 4431

Group type: EXPERIMENTAL
Intervention: Predictors for headache during CVE
Number of subjects: 4431
Study: 23749683

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (ICT)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: ICT combined with gemtuzumab ozogamicin (ICT+GO)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Number of subjects: 393
Study: 23750331

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg) with THC/CBD spray (10.8/10 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg) with THC/CBD spray (10.8/10 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Omeprazole (40 mg) with THC/CBD spray (10.8/10 mg)
Number of subjects: 36
Study: 23751980

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) - aspirin plus an NAAA
Number of subjects: 28696

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 28696

Group type: EXPERIMENTAL
Intervention: Nonaspirin antiplatelet agents (NAAAs)
Number of subjects: 28696

Group type: COMPARATOR
Intervention: Nonusers (no antiplatelet drugs)
Number of subjects: 28696
Study: 23752171

Group type: COMPARATOR
Intervention: 2 annual preventive visits (LoR)
Number of subjects: 5117

Group type: COMPARATOR
Intervention: 1 annual preventive visit (LoR)
Number of subjects: 5117

Group type: COMPARATOR
Intervention: 2 annual preventive visits (HiR)
Number of subjects: 5117

Group type: COMPARATOR
Intervention: 1 annual preventive visit (HiR)
Number of subjects: 5117
Study: 23752175

Group type: EXPERIMENTAL
Intervention: KPT-276
Number of subjects: 12
Study: 23753021

Group type: EXPERIMENTAL
Intervention: Rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine followed by consolidation with (90)Y-ibritumomab tiuxetan
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Consolidation therapy with (90)Y-ibritumomab tiuxetan
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induction treatment
Number of subjects: 30
Study: 23753028

Group type: EXPERIMENTAL
Intervention: Rituximab, gemcitabine and oxaliplatin
Number of subjects: 49
Study: 23753030

Group type: EXPERIMENTAL
Intervention: Rituximab infusions and intensive chemotherapy (high-dose methotrexate, fractionated ifosfamide/cyclophosphamide, other drugs in rotation, intrathecal chemoprophylaxis)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Rituximab infusions and intensive chemotherapy
Number of subjects: 105
Study: 23753102

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (maximum oxygen uptake, mL/kg/min) measured with a maximal cycle ergometer test
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (maximum oxygen uptake, mL/kg/min)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Lifestyle counseling (not associated with fitness)
Number of subjects: 341
Study: 23754469

Group type: EXPERIMENTAL
Intervention: Gelatin-thrombin matrix
Number of subjects: 20
Study: 23754575

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) with rifampin (CYP3A inducer)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) with ketoconazole (CYP3A inhibitor)
Number of subjects: 56
Study: 23754628

Group type: COMPARATOR
Intervention: Standard therapy alone (Control)
Number of subjects: 562
Study: 23754824

Group type: EXPERIMENTAL
Intervention: Food reinforcement
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Household income
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Indirect effect of household income
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Education level as proxy for SES
Number of subjects: 166
Study: 23756334

Group type: EXPERIMENTAL
Intervention: Sympathetic arousals during sleep (measured by autonomic arousal index, AAI)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Sympathetic arousals during sleep (measured by AAI)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Increased AAI
Number of subjects: 780
Study: 23756764

Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg, 20 mg, 25 mg) and Sorafenib (200 mg, 400 mg) given orally once daily for 28 days (1 cycle).
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Lenalidomide and Sorafenib treatment.
Number of subjects: 41
Study: 23756775

Group type: EXPERIMENTAL
Intervention: Emergency repairs
Number of subjects: 10976

Group type: COMPARATOR
Intervention: Elective repairs
Number of subjects: 10976
Study: 23757434

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Self-monitored blood glucose (BG)
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Estimated Average Glucose (AG)
Number of subjects: 1879
Study: 23758300

Group type: EXPERIMENTAL
Intervention: CE+EUS
Number of subjects: 387

Group type: COMPARATOR
Intervention: CE
Number of subjects: 387
Study: 23758943

Group type: EXPERIMENTAL
Intervention: Hypovitaminosis D
Number of subjects: 9305
Study: 23759033

Group type: EXPERIMENTAL
Intervention: Treatment-seeking overweight youth (parent-reported HRQoL)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Treatment-seeking overweight youth (self-reported HRQoL)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Treatment-seeking status
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Perceived overweight status
Number of subjects: 137
Study: 23760428

Group type: COMPARATOR
Intervention: Escitalopram (selective serotonin reuptake inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ω-3 supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine (serotonin-norepinephrine reuptake inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose oral estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23760766

Group type: EXPERIMENTAL
Intervention: 3-week inpatient program combining rehabilitative treatment and preventive, psychosocial, child-centered interventions
Number of subjects: 116
Study: 23761092

Group type: EXPERIMENTAL
Intervention: Continuous intraoperative optical coherence tomography (OCT) measurements of anterior lens capsule position after removing the crystalline lens and after implanting a capsular tension ring (CTR).
Number of subjects: 70

Group type: COMPARATOR
Intervention: Preoperative ACD measurements.
Number of subjects: 70
Study: 23761380

Group type: EXPERIMENTAL
Intervention: LC-MS/MS assay for serum cortisol analysis
Number of subjects: 320

Group type: COMPARATOR
Intervention: Immunoassays (Roche and Abbott)
Number of subjects: 320

Group type: COMPARATOR
Intervention: GC-MS assay
Number of subjects: 320
Study: 23761401

Group type: EXPERIMENTAL
Intervention: Circulating progenitor cells (PCs) with higher serum SDF-1α levels and reduced spontaneous motility in an in vitro migration assay.
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Percentage of PCs non-migrated towards vehicle or SDF-1α.
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Serum SDF-1α levels.
Number of subjects: 172
Study: 23761422

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (r-hGH) therapy
Number of subjects: 103
Study: 23761643

Group type: EXPERIMENTAL
Intervention: Timed-spot urine specimens (morning, afternoon, evening, overnight)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Timed-spot urine specimens (overnight)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: 24-h urine samples
Number of subjects: 407
Study: 23762229

Group type: EXPERIMENTAL
Intervention: Trivalent flu vaccine (AdimFlu-S®) 15 mcg of hemagglutinin for each strain/0.5 mL
Number of subjects: 46
Study: 23763450

Group type: EXPERIMENTAL
Intervention: Neuropsychological Test Battery (NTB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog)
Number of subjects: 0
Study: 23763917

Group type: EXPERIMENTAL
Intervention: Barasertib (800 mg, 1000 mg, 1200 mg) plus low-dose cytosine arabinoside (LDAC) 20 mg (subcutaneous injection twice daily for 10 days) administered in 28-day cycles.
Number of subjects: 22
Study: 23764537

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 27
Study: 23764909

Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction and elevated troponin level
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Either right ventricular dysfunction or elevated troponin level
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Overall model including both dysfunction and injury
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: No dysfunction or injury
Number of subjects: 1515
Study: 23765437

Group type: EXPERIMENTAL
Intervention: VKA therapy
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Overall occurrence of in-hospital major adverse cardiac events
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Bleeding complications
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Female gender/treatment with gpIIb/IIIa-antagonists
Number of subjects: 963
Study: 23765752

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: MHOS
Number of subjects: 92
Study: 23768574

Group type: EXPERIMENTAL
Intervention: Sublingual allergen immunotherapy (specific dosage and duration not available)
Number of subjects: 0
Study: 23769088

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) + reduced exposure tacrolimus (rTAC)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Standard tacrolimus (TAC)
Number of subjects: 719
Study: 23769498

Group type: EXPERIMENTAL
Intervention: Target fortified breast milk (fat: 4.4 g, protein: 3 g, carbohydrates: 8.8 g per 100 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine fortification of breast milk
Number of subjects: 20
Study: 23770158

Group type: EXPERIMENTAL
Intervention: Enzastaurin (250 mg oral, 125 mg tablets twice a day; a 1125-mg loading dose on day 1)
Number of subjects: 57
Study: 23770972

Group type: EXPERIMENTAL
Intervention: 100 mg/day aspirin
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 100 mg/day aspirin plus 40 mg/day atorvastatin
Number of subjects: 299

Group type: COMPARATOR
Intervention: X-CGD patients
Number of subjects: 299

Group type: COMPARATOR
Intervention: T2D patients
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: In vitro study
Number of subjects: 299
Study: 23771742

Group type: EXPERIMENTAL
Intervention: Ambulatory surgery
Number of subjects: 0
Study: 23772042

Group type: EXPERIMENTAL
Intervention: Tigecycline as monotherapy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tigecycline as combination therapy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tigecycline for nosocomial infections
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tigecycline for patients with APACHE II score >15
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tigecycline for patients with SOFA score ≥ 7
Number of subjects: 254
Study: 23772045

Group type: EXPERIMENTAL
Intervention: Tigecycline (used alone or in combination)
Number of subjects: 1039
Study: 23772047

Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg plus 50 mg twice daily) for a mean duration of 11.1 ± 6.4 days
Number of subjects: 1782
Study: 23773637

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation (MSCT)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control treatment (monthly pulse-cyclophosphamide + azathioprine + prednisolone)
Number of subjects: 3
Study: 23774433

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg (adolescents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine 15 mg/kg (children aged 2 to 12 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine 15 mg/kg (children 2 to 12 years)
Number of subjects: 0
Study: 23775962

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg once per day or 400 mg twice per day if no initial response
Number of subjects: 25
Study: 23777553

Group type: EXPERIMENTAL
Intervention: Patients with OSAHS
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study: 23777764

Group type: EXPERIMENTAL
Intervention: MDASI-CML administered to patients every 2 weeks for 1 year
Number of subjects: 152
Study: 23778184

Group type: EXPERIMENTAL
Intervention: Optical frequency domain imaging (OFDI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (no intervention on identified FS)
Number of subjects: 97
Study: 23778400

Group type: EXPERIMENTAL
Intervention: Forced oscillation technique
Number of subjects: 67

Group type: COMPARATOR
Intervention: Spirometry
Number of subjects: 67
Study: 23778831

Group type: EXPERIMENTAL
Intervention: Arginine administration
Number of subjects: 0
Study: 23780842

Group type: EXPERIMENTAL
Intervention: High resolution microendoscopy (HRME) by expert microendoscopists
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High resolution microendoscopy (HRME) by novice microendoscopists
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall HRME performance
Number of subjects: 68
Study: 23782005

Group type: EXPERIMENTAL
Intervention: ATV/RTV 300/100 mg once daily with zidovudine/lamivudine 300/150 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ATV/RTV 400/100 mg once daily with zidovudine/lamivudine 300/150 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ATV/RTV treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maternal UGT1A1 genotype
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neonatal UGT1A1 genotype or cord blood ATV concentration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ATV/RTV treatment of mothers
Number of subjects: 40
Study: 23782158

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 85
Study: 23782157

Group type: EXPERIMENTAL
Intervention: Ibrutinib, 560 mg daily
Number of subjects: 111
Study: 23782492

Group type: EXPERIMENTAL
Intervention: Nocturnal continuous positive airway pressure (CPAP) treatment
Number of subjects: 44
Study: 23782511

Group type: EXPERIMENTAL
Intervention: BM-MSCs therapy (5 × 10(7) cells injected twice through the hepatic artery at weeks 4 and 8)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BM-MSCs therapy
Number of subjects: 12
Study: 23782682

Group type: EXPERIMENTAL
Intervention: Haploidentical peripheral blood stem cell infusions (1-2x10^8 CD3+ cells/kilogram)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Monitoring for cytokine release syndrome (CRS)
Number of subjects: 25
Study: 23782711

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus low-dose dexamethasone (25 mg/day, adjusted for renal function)
Number of subjects: 199
Study: 23783429

Group type: EXPERIMENTAL
Intervention: Rapidly-generated trivirus-directed T cells
Number of subjects: 12
Study: 23784912

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 14343

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 14343

Group type: EXPERIMENTAL
Intervention: Body Adiposity Index (BAI)
Number of subjects: 14343

Group type: EXPERIMENTAL
Intervention: Waist-to-Height Ratio (WHtR)
Number of subjects: 14343

Group type: EXPERIMENTAL
Intervention: Waist-to-Hip Ratio (WHR)
Number of subjects: 14343

Group type: EXPERIMENTAL
Intervention: Waist circumference (categorical analysis)
Number of subjects: 14343